Rafael Holdings, Inc. /
Cyclo Therapeutics, Inc.
Rafael Holdings completes combination with Cyclo Therapeutics
What happened
Rafael Holdings, Inc. completed its business combination with Cyclo Therapeutics, Inc. on March 25, 2025. Rafael issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders, representing approximately 22% of the combined company.
Cyclo Therapeutics is a clinical-stage biotechnology company focused on developing medicines for patients and families living with disease.
Who is involved, and the source
Everything on this page comes from the source below.
Advisers
Buy side
- Legal adviser to the buyerSchwell Wimpfheimer & AssociatesSource-verified
Target
- Legal adviser to the targetFox Rothschild LLPSource-verified
Advisers are not parties to the deal.
Rafael Holdings completes combination with Cyclo Therapeutics
This document is the source for the companies, stage and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly